Results 151 to 160 of about 4,218 (200)

Comparison of the influence of 1% and 0.01% atropine on the corneal topography in myopic children. [PDF]

open access: yesBMC Ophthalmol
Zhao LQ   +8 more
europepmc   +1 more source

Therapeutic Potential of 1-(2-Chlorophenyl)-6,7-dimethoxy-3-methyl-3,4-dihydroisoquinoline. [PDF]

open access: yesMolecules
Slavchev V   +5 more
europepmc   +1 more source

Habu snakes (Protobothrops flavoviridis) show variation in thoracic aortic vasoreactivity between adjacent Japanese islands. [PDF]

open access: yesJ Vet Med Sci
Ootawa T   +8 more
europepmc   +1 more source

Pharmacological interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units: a network meta-analysis. [PDF]

open access: yesBMJ Evid Based Med
Toews I   +11 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Pyrimidobenzodiazepines. Synthesis of pirenzepine analog.

Die Pharmazie, 1990
The synthesis of Pyrimido[4,5-b][1,5]benzodiazepine derivatives from 4-(o-aminophenylene)amino-5-ethoxy-carbonyl-1,2-dihydro-6-methyl-2 - oxopyrimidine has been described. Pyrimidobenzodiazepine 5 alkylated with N-methyl-N'-chloroacetyl-piperazine gives a product related to pirenzepine. Compound 5 shows weak antianxiety and antidepressive action.
Długosz, Anna, Machoń, Zdzisław
openaire   +2 more sources

Central oxotremorine antagonist properties of pirenzepine

Life Sciences, 1988
Pirenzepine, the prototype M1 muscarinic receptor antagonist, is an important compound for investigating the functional significance of M1 receptors at the integrated level of behavior but may have limitations imposed by its physical chemistry. Like the nonselective antagonist methylatropine, pirenzepine is highly hydrophilic and crosses the blood ...
J M, Witkin   +3 more
openaire   +2 more sources

Pirenzepine and Gastrointestinal Motility: Differential Effect of Pirenzepine in the Gut

1985
The capacity of pirenzepine to reduce gastric acid secretion in the basal state and after various forms of stimulation is well established by now (Jaup 1981). It is still under discussion whether the ulcer-healing and symptom-relieving effect of pirenzepine is solely due to the moderate acid reduction observed or whether other pharmacological ...
R. W. Stockbrügger   +3 more
openaire   +1 more source

PLASMA AND BILIARY DISPOSITION OF PIRENZEPINE IN MAN

Clinical and Experimental Pharmacology and Physiology, 1986
SUMMARY1. The binding of pirenzepine, a selective muscarinic receptor antagonist to plasma and bile, was studied in vitro and in vivo. Plasma and hepatic bile were incubated with 14C‐pirenzepine and the bound fraction of 14C‐pirenzepine determined by equilibrium dialysis. The bound fractions were 12.6% (s.e.m.
Lee, SP, Paxton, JW, Choong, YS
openaire   +4 more sources

Absolute bioavailability of pirenzepine in intensive care patients

European Journal of Clinical Pharmacology, 1990
The absolute bioavailability (f) of pirenzepine was determined in 27 intensive care patients receiving the drug for prophylaxis and therapy of upper gastrointestinal tract bleeding. A multiple oral and intravenous dosage regimen and the times of blood sampling were adapted to individual conditions and treatment.
P, Tanswell   +5 more
openaire   +2 more sources

Pirenzepine Inhibits Pancreatic Exocrine Secretion in the Rat

Pancreas, 1986
Pirenzepine is a newly developed anticholinergic drug that reduces gastric acid secretion and is therefore used in Europe and Japan to treat patients with peptic ulcer. The inhibitory effect of pirenzepine on pancreatic exocrine function and its reversibility were studied in the isolated pancreatic acini and the isolated perfused pancreas of rats.
M, Otsuki   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy